Vertex stock jumps after interim phase III data show povetacicept cuts proteinuria 52% in IgA nephropathy study and boost hopes for accelerated FDA approval.

Vertex Pharmaceuticals (NASDAQ:VRTX) shares rose 6% to $488.52 in premarket trading Thursday after the company reported successful results from a late-stage trial ...

Vertex delivers tax technology software and SaaS solutions to corporations seeking streamlined compliance and integration capabilities.

Check out some of the companies making the biggest moves midday: Hims & Hers Health — Shares of the telehealth company jumped ...

Vertex Pharmaceuticals shares surged Tuesday after the company posted promising results from a clinical trial of a drug to treat kidney disease.

Vertex Pharmaceuticals (VRTX) stock climbed 5% after povetacicept showed strong phase 3 results in IgA nephropathy, with FDA filing planned by March.

The drug maker says its treatment of a rare kidney disease met its main goal in a late-stage trial.

Kohl's — Shares tumbled 9% after the retailer posted disappointing fourth-quarter revenue of $4.97 billion, below the LSEG consensus of $5.03 billion. On the other hand, fourth quarter earnings of $1.

↘️ Boeing (BA): The plane maker will delay some 737 MAX deliveries after discovering a problem with wiring. The stock was down 3.2%. ↗️ Micron Technology (MU), Applied Materials (AMAT): The companies ...

Major stock indexes closed mostly lower Tuesday even though oil prices fell, as investors digested conflicting Iran war developments.

US stock market Dow Jones futures moved higher today as global risk eased. Dow futures rose to 47,796, up 27 points in early trading. S&P 500 futures reached 6,803, while Nasdaq futures climbed to 25, ...